Home Archives 2013 April

Monthly Archives: April 2013

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for April 16 2013

TradenameApplicantGeneric Name Patent Expiration
ACUTECTCis Bio Intl Satechnetium tc-99m apcitideApr 16, 2013
CAVERJECT IMPULSEPharmacia And UpjohnalprostadilApr 16, 2013
GENOTROPIN PRESERVATIVE FREEPharmacia And Upjohnsomatropin recombinantApr 16, 2013
NICODERM CQSanofi Aventis UsnicotineApr 16, 2013
OXYCONTINPurdue Pharma Lpoxycodone hydrochlorideApr 16, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Future drug patent expirations by month

How Many Drug Patents Will Expire in the Coming Months?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for April 14 2013

TradenameApplicantGeneric Name Patent Expiration
RAPLONOrganon Usa Incrapacuronium bromideApr 14, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which pharma companies have the most drug patents

Which Companies Have the Most Active Drug Patents?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

As I continue to investigate global biotechnology for Scientific American and international patenting trends for DrugPatentWatch.com, I came across a curious finding.

I was looking at the global spread of US drug patents — to obtain global patent protection for drugs companies must file for patents in each of the jurisdictions that they seek protection, within 12 months of the initial filing. Patents last for roughly 20 years, which means that current patent activity reflects a 20-year forward-looking sentiment on the attractiveness of a market.

global filings of us drug patentsWhen comparing India and China one sees an interesting trend. Before the 1980s there was little interest in obtaining patent protection in either country. In fact, it wasn’t possible in India because the country had not yet adopted the TRIPS accords which permit product patents. Over the course of the 1980s and 1990s interest in China increased, stabilizing at roughly 70% representation of US drug patents in that market.

In 2005 India adopted the TRIPS accords and (partially*) permitted product patents, so it would be very interesting to observe how global patenting trends were affected by the new ability to obtain pharmaceutical product patents there. Unfortunately, in 2005 Indian sources stopped sharing patent data with the European Patent Office, which serves as a global clearinghouse of patent globally-linked patents. This lack of transparency makes it impossible to determine global interest in the Indian market, and  robs India the opportunity to tell the story of the impact of taking steps towards harmonizing their patent system.

*An important exception in India’s patent law is that new drug products must offer substantial new efficacy relative to existing products. This has been at the center of Novartis’ patent disputes in India.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for April 3 2013

TradenameApplicantGeneric Name Patent Expiration
BROVANASunovionarformoterol tartrateApr 3, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which pharmaceutical companies have the most drugs

Which Companies Have the Most Branded Drugs?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

I continue to measure global biotechnology innovation in the fifth  edition of Scientific American Worldview. This special publication is the foundation I use for my talks on global biotechnology (see my recent talk on Building Biotechnology in India).

I will be serving on a panel on April 24th at 2pm, and Fareed Zakaria will be moderating a discussion with industry leaders at 3:30.

In addition to the comparative global biotechnology innovation scorecard which I edit, Worldview also includes subjective stories of global innovation, highlights of selected countries, and profiles of industry leaders.

I look forward to your comments and critiques — check out Scientific American Worldview at http://www.saworldview.com

Pharma companies with the most drug approvalsThis infographic from DrugPatentWatch shows that Sanofi Aventis UsMerckGlaxosmithklineAbbvieAbraxis BioscienceGenzymeAbbott Endocrine,Boehringer IngelheimMerck And Co Inc, and Vyteris face the most patent expirations this year. Perhaps not surprisingly, GlaxoSmithKline and Sanofi Aventis are also among the firms with the most drug patents.

For more infographics, see the DrugPatentWatch Pharmaceutical Innovation Infographics.

Do you have a response to this infographic? Respond in the comments section below.

Join Michael Salgaller and I as we will be signing our books at the BIO bookstore on Tuesday April 23rd.

Michael will be signing Biotechnology Entrepreneurship From Science to Solutions from 12:30 to 2pm.

I will be signing Building Biotechnology, Best Practices in Biotechnology Business Development, the Journal of Commercial Biotechnology, and also giving demos of DrugPatentWatch.com and BiologicPatentWatch.com from 2pm – 3:30.

Stop by to chat about or books, or for a casual conversation.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for March 26 2013

TradenameApplicantGeneric Name Patent Expiration
LOVAZASmithkline Beechamomega-3-acid ethyl estersMar 26, 2013
SILENORSomaxondoxepin hydrochlorideMar 26, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which drug companies face the most patent expirations

Which Companies Face the Most Patent Expirations?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below.

Susan Kling FinstonA common first reaction to crowdfunding for life sciences may be to dismiss it out of hand. Given the undeniable chill in early stage funding, it is worth giving the idea a more serious look. Or, in the immortal words of Sherlock Holmes, “When you have eliminated the impossible, whatever remains, however improbable, must be the truth.”

The improbable truth is that Kickstarter has helped to raise millions through crowdsourcing to fund creativity in the arts and digital sciences. In 2012 alone, Kickstarter helped to raise over $100 million for new games projects. Most recently, The Veronica Mars Movie Project closed out its Kickstarter funding campaign successfully, far exceeding its goal with pledges of over $5.7 million raised from fans in 30 days. Every Kickstarter project, though, must fit into fixed categories. Under the heading of “What is not allowed,” Kickstarter states that “Projects cannot offer financial, medical, or health advice.” Like Seinfeld’s Soup Nazi, Kickstarter has ‘no soup’ for projects related to the innovative life sciences.

So crowdfunding portals for bio-pharma and medical devices are springing up like new grass after the rain in the U.S. and overseas, hoping to replicate Kickstarter’s success. As expressed by Sarah Lacy of Pandodaily: 

“Hey, it worked for watches and robots on Kickstarter. And if we can donate $100 to finance a watch we may never see or an indie movie that does little for mankind, is it so crazy to take a flier on cancer research?”

The real challenge is how to choose among the alternatives – mainly recent entrants without a track record of raising the kinds of funds needed for translational research. indiegogo, although not a science-dedicated site, may have raised the most for R&D, helping the iCancer project to raise over $150,000 (though falling far short of a $1m goal, the non-profit has received funds pledged). The most well-wired and promoted of the dedicated crowdfunding sites may be MedStartr, which has adopted the “Startr” moniker that Kickstarter began with (before adding the “e”). Other U.S.-based dedicated crowdfunding sites that are science-dedicated include Microryza iAMscientist, PetriDish (primarily natural sciences) and SciFlies. Based on my initial review of the alternatives, Microryza stands out from the crowd due to the direct experience of the founders that led to the start of the company, and with an approach that is both engaging/accessible and provides gravitas to research projects on the site.

Time will tell whether bio-entrepreneurs can leverage crowdfunding for successful fundraising, and which of the current (or future) crop may become the Kickstarter of innovative life science. Stay tuned!

Susan K. Finston is President of Finston Consulting LLC, and, together with biotechnology pioneer Ananda Chakrabarty, is co-founder of Amrita Therapeutics Ltd., an emerging biopharmaceutical company based in India with cancer peptide drugs entering in vivoresearch. She is currently preparing to launch her first Crowd Funding campaign for Amrita Therapeutics first-ever therapeutic oncology medical device. For more information see AmritaTherapeutics.com or FinstonConsulting.com.